<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220127</url>
  </required_header>
  <id_info>
    <org_study_id>14/0050</org_study_id>
    <secondary_id>14/LO/0791</secondary_id>
    <secondary_id>145268</secondary_id>
    <nct_id>NCT02220127</nct_id>
  </id_info>
  <brief_title>RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases</brief_title>
  <official_title>Optimal Radiation Method for Gamma Knife Radiosurgery of Brain Micrometastases: A Multi-centre Randomised Clinical Trial (RCT) of the 4mm vs. the 8mm Collimator.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gamma Knife Radiosurgery (GKR) is a well-established treatment modality for brain metastasis&#xD;
      (Chiou 2013; Salvetti, Nagaraja et al. 2013). Large multicentre series have been published on&#xD;
      patients with single and multiple cerebral metastases, treated with GKR over a period of 30&#xD;
      years (Karlsson, Hanssens et al. 2009). Multiple institutions have reported a consistently&#xD;
      high local tumour control rate of 80%-90% following GKR (Chang, Lee et al. 2000; Da Silva,&#xD;
      Nagayama et al. 2009; Salvetti, Nagaraja et al. 2013).&#xD;
&#xD;
      There is controversy over the use of GKR and/or Whole Brain Radiotherapy (WBRT) in patients&#xD;
      with multiple metastases. WBRT provides a lower rate of distant recurrences, whereas GKR&#xD;
      achieves good local control of treated lesions without the deleterious side effects of&#xD;
      radiotherapy (Lippitz, Lindquist et al. 2014). This discussion is mainly focused on the risk&#xD;
      of distant recurrences, which is lower if WBRT is given. There is evidence showing that&#xD;
      Radiosurgery (RS) based on high contrast/resolution stereotactic MRI decreases the incidence&#xD;
      and lengthens the time to distant recurrences (Hanssens, Karlsson et al. 2011). As a result,&#xD;
      the current tendency is to treat all the lesions visible in high contrast/resolution images&#xD;
      the day of Gamma Knife; which is followed by regular MRI follow ups and subsequent GKR for&#xD;
      distant recurrences in order to avoid/delay WBRT.&#xD;
&#xD;
      It has been estimated that more than a half of distant recurrences will grow from tumour&#xD;
      cells that were already in the brain (as micrometastases) when radiosurgery is delivered, but&#xD;
      not much has been studied on the optimal prescription and radiation delivery method for these&#xD;
      lesions. There is controversy over which collimator should be used when treating&#xD;
      micro-metastases (BmM). These lesions can either be treated with the 4mm collimator at an&#xD;
      isodose between the 40% and 90%, or the 8mm collimator at an isodose above 90%. The 8 mm&#xD;
      collimator is thought to offer better Local Control Rate (LCR) with the advantage of faster&#xD;
      delivered treatments, while the 4 mm collimator is considered to be safer, given its steep&#xD;
      dose fall-off. It is the aim of this study to find out which of the 4 mm or 8 mm collimators&#xD;
      can achieve the higher LCR with less complications. A large number of lesions will be&#xD;
      randomised to either the 4 or the 8 mm collimator and the patients followed up to evaluate&#xD;
      clinical efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate (LCR)</measure>
    <time_frame>up to 24 months after treatment</time_frame>
    <description>LCR will be evaluated through volumetric assessment of the lesion the day of Gamma Knife and in subsequent follow up MRI scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse radiation effects (ARE)</measure>
    <time_frame>up to two years</time_frame>
    <description>The following radiological and clinical outcomes will be used to assess ARE:&#xD;
Bleeding from randomised lesions, Perilesional radiation induced necrosis, Severe peri-lesional oedema, New onset or worsened neurological deficit attributable to a randomised lesion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Brain Micrometastases</condition>
  <arm_group>
    <arm_group_label>8 mm collimator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GKR with a single shot of the 8 mm collimator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mm collimator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GKR with a single shot of the 4 mm collimator</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>GKR with a single shot of the 8 mm collimator</intervention_name>
    <description>Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.</description>
    <arm_group_label>8 mm collimator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>GKR with a single shot of the 4 mm collimator</intervention_name>
    <description>Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.</description>
    <arm_group_label>4 mm collimator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with brain metastasis from any primary tumour receiving GKR.&#xD;
&#xD;
          -  All intracranial micro-metastases including lesions located in the cerebral&#xD;
             hemispheres, thalamus, basal ganglia and cerebellum and excluding lesions located in&#xD;
             the brain stem below the level of the superior colliculi.&#xD;
&#xD;
          -  Target volume &lt; 0.14 cc3 and maximum diameter &lt; 7 mm.&#xD;
&#xD;
          -  The subject consents to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Younger than 18 years of age.&#xD;
&#xD;
          -  Lesions in the brainstem (below the level of the superior colliculi) are better&#xD;
             treated with the 4 mm collimator and they will be excluded from the study.&#xD;
&#xD;
          -  Patients with more than 25 brain lesions suitable for randomisation will be excluded&#xD;
             from the study.&#xD;
&#xD;
          -  Co-morbidity or previous treatment such as surgery, chemotherapy or WBRT is not to be&#xD;
             considered as exclusion criteria.&#xD;
&#xD;
          -  Pregnancy in the context of brain metastases is not a contraindication for GKR, and&#xD;
             therefore it will not be considered as exclusion criteria for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Kitchen, Mr</last_name>
    <role>Study Chair</role>
    <affiliation>The National Hospital for Neurology and Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alvaro Villabona, Dr</last_name>
    <phone>+44 020 3448 4076</phone>
    <email>a.villabona.11@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gamma Knife Centre at BUPA Cromwell Hospital</name>
      <address>
        <city>London</city>
        <zip>SW5 0TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bodo Lippitz, MD</last_name>
      <phone>020 7460 5938</phone>
      <email>bodo.lippitz@cromwellhospital.com</email>
    </contact>
    <investigator>
      <last_name>Bodo Lippitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christer Lindquist, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Gamma Knife Centre at Queen Square</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Villabona, Dr</last_name>
      <phone>+44 020 3448 4076</phone>
      <email>a.villabona.11@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Ian Paddick, MSc,MIPM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naomi Fersht, PhD, FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolf Jäger, MD, FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Miszkiel, MRCP, FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alvaro Villabona, MBBS, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil Kitchen, MD, FRCS(SN)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BMI Thornbury Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 3BR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andras Kemeny, FRCS, MD</last_name>
      <phone>01142674651</phone>
      <email>aakemeny@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andras Kemeny, FRCS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Radatz, FRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Rowe, FRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Neoplasm Micrometastasis</keyword>
  <keyword>Gamma Knife Radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Micrometastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

